GlaxoSmithKline receives FDA approval for advanced renal cell carcinoma treatment
GlaxoSmithKline has received approval from the US Food and Drug Administration (FDA) for the Votrient (pazopanib) drug. The drug is approved for the treatment of patients with advanced renal cell carcinoma (RCC), a form of kidney cancer. The FDA’s Oncologic Drugs Advisory Committee (ODAC) had earlier voted unanimously in favor of the drug due to encouraging results from the phase III trial.
- Argos Therapeutics Presents Positive Phase 2 Data For Arcelis(TM) Dendritic Cell-based Immunotherapy
- Genentech receives FDA approval for kidney cancer treatment
- Teva receives approval for generic Eloxatin
- Spectrum Pharma receives FDA approval for Zevalin
